Table 3 Comparison of echocardiographic parameters at baseline and after 3 months of treatment for the study groups.

From: Effect of trimetazidine on left ventricular functions and cardiac biomarkers in diabetic patients with left ventricular diastolic dysfunction: a randomized controlled trial

Variables

 

TMZ group (n = 30)

Placebo group (n = 29)

p-value

LVEDD (mm)

Baseline

48.73 ± 3.81

49.24 ± 5.65

0.686a

After 3 months

49.36 ± 3.56

49.52 ± 3.69

0.874a

% change

1.54 ± 6.78

1.15 ± 7.29

0.83a

LVESD (mm)

Baseline

30.7 ± 3.16

30.89 ± 4.78

0.853a

After 3 months

30.53 ± 3

31.34 ± 4.02

0.382a

% change

−0.01 ± 10.14

2.06 ± 8.9

0.408a

LAD (mm)

Baseline

40.3 ± 5.07

39.48 ± 4.03

0.497a

After 3 months

39 ± 4.99

40.07 ± 4.48

0.391a

% change

−2.65 ± 11.32

1.91 ± 10.66

0.117a

RWT

Baseline

0.39 ± 0.04

0.401 ± 0.04

0.552a

After 3 months

0.39 ± 0.05

0.41 ± 0.04

0.263a

% change

−0.09 ± 10.32

2.86 ± 15.93

0.404a

LVMI (g/m2)

Baseline

85.94 ± 14.77

86.68 ± 18.96

0.868a

After 3 months

88.52 ± 14.97

91.18 ± 20.18

0.567a

% change

5.19 ± 22.99

6.44 ± 18.45

0.819a

LVEDVI (ml/m2)

Baseline

39.88 ± 7.49

41.79 ± 9.38

0.392a

After 3 months

38.4 ± 6.8

38.51 ± 8.34

0.957a

% change

−2.48 ± 14.59

−6.39 ± 14.42

0.304a

LVESVI (ml/m2)

Baseline

15.44 ± 3.47

16.71 ± 4.62

0.237a

After 3 months

14.92 ± 3.64

15.83 ± 4.29

0.382a

% change

−1.56 ± 22.14

−2.58 ± 20.87

0.856a

EF %

Baseline

61.36 ± 5.02

61.55 ± 4.06

0.877 a

After 3 months

61.83 ± 4.89

59.41 ± 3.41

0.032*a

% change

1.59 ± 13.12

−3.28 ± 5.26

0.068a

E (cm/s)

Baseline

69.86 ± 14.67

70.24 ± 17.37

0.929 a

After 3 months

73.76 ± 16.25

72.62 ± 17.86

0.797a

% change

6.75 ± 17.64

5.2 ± 21.59

0.763a

A (cm/s)

Baseline

87.66 ± 13.74

79 ± 12.45

0.014*a

After 3 months

85.26 ± 14.27

78.83 ± 13.63

0.082a

% change

−2.22 ± 10.84

0.04 ± 9.64

0.402a

E/A ratio

Baseline

0.79 ± 0.13

0.89 ± 0.19

0.035*a

After 3 months

0.87 ± 0.16

0.93 ± 0.2

0.237a

% change

9.15 ± 13.29

5.04 ± 18.47

0.329a

DT (ms)

Baseline

190.7 ± 35.82

193.41 ± 43.31

0.794a

After 3 months

194.76 ± 34.37

198.03 ± 39.31

0.737a

% change

4.37 ± 22.12

2.39 ± 32.91

0.786a

LAVI (ml/m2)

Baseline

31.54 ± 7.36

30.48 ± 6.28

0.555a

After 3 months

28.77 ± 5.55

30.39 ± 6.53

0.307a

% change

−6.99 ± 13.68

0.66 ± 13.39

0.034*a

Septal e’ (cm/s)

Baseline

6.43 ± 1.33

6.82 ± 1.58

0.304a

After 3 months

7.13 ± 1.36

6.62 ± 1.42

0.162a

% change

13.06 ± 19.92

−0.96 ± 18.35

0.007*a

Lateral e’ (cm/s)

Baseline

8.96 ± 2.44

8.34 ± 1.95

0.285a

After 3 months

9.2 ± 2.01

8 ± 1.79

0.019*a

% change

6.69 ± 23.45

−2.09 ± 19.63

0.124a

Average e’ (cm/s)

Baseline

7.7 ± 1.71

7.58 ± 1.63

0.795a

After 3 months

8.16 ± 1.53

7.29 ± 1.45

0.028*a

% change

8.46 ± 18.64

−2.49 ± 14.52

0.015*a

Average E/ e’ ratio

Baseline

9.51 ± 3.21

9.48 ± 2.37

0.969 a

After 3 months

9.23 ± 2.34

10.19 ± 2.9

0.167a

% change

0.03 ± 17.96

9.39 ± 23.91

0.094a

LVGLS %

Baseline

−17.01 ± 1.98

−17.27 ± 3.45

0.717a

After 3 months

−18.02 ± 2.35

−16.65 ± 3.02

0.056a

% change

6.66 ± 13.88

−2.79 ± 9.64

0.004*a

  1. Data were presented as mean ± standard deviation; LVEDD: left ventricular end diastolic dimension; LVESD: left ventricular end systolic dimension; LAD: left atrial diameter; LVMI: left ventricular mass index; RWT: relative wall thickness; LVEDVI: left ventricular end diastolic volume index; LVESVI: left ventricular end systolic volume index; EF: ejection fraction; E: peak early trans-mitral flow velocity ; A:peak late trans-mitral flow velocity; DT: deceleration time; LAVI: left atrial volume index; e’: peak early diastolic velocity of mitral annular motion; LVGLS: left ventricular global longitudinal strain. Statistical tests: a Un-paired student t-test, p-value ≥ 0.05; * p-value< 0.05 is statistically significant.